{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:44:54Z","timestamp":1792071894258,"version":"4.4.0"},"reference-count":64,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Sacituzumab Govitecan (SG) is an antibody-drug conjugate (ADC) comprised of an anti-Trop-2 IgG1 molecule conjugated to SN-38, the active metabolite of irinotecan, via a pH-sensitive hydrolysable linker. As a result of recent Canadian funding for SG in advanced hormone receptor (HR)-positive breast cancer and triple-negative breast cancer (TNBC), experience with using SG and managing adverse events (AEs) has grown. This review presents a summary of evidence and adverse event recommendations derived from Canadian experience, with SG use in metastatic TNBC for extrapolation and guidance in all indicated settings. SG is dosed at 10 mg\/kg on day 1 and day 8 of a 21-day cycle. Compared to treatment of physicians\u2019 choice (TPC) the phase III ASCENT and TROPiCS-02 studies demonstrated favorable survival data in unresectable locally advanced or metastatic TNBC and HR-positive HER2 negative metastatic breast cancer, respectively. The most common AEs were neutropenia, diarrhea, nausea, fatigue, alopecia, and anemia. This review outlines AE management recommendations for SG based on clinical trial protocols and Canadian guidelines, incorporating treatment delay, dose reductions, and the use of prophylactic and supportive medications.<\/jats:p>","DOI":"10.3390\/curroncol31090422","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T09:16:10Z","timestamp":1727428570000},"page":"5694-5708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-7913","authenticated-orcid":false,"given":"Mita","family":"Manna","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada"},{"name":"Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"},{"name":"Saskatoon Cancer Centre, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Brabant","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8922-9815","authenticated-orcid":false,"given":"Rowen","family":"Greene","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Microbiology, and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-8545","authenticated-orcid":false,"given":"Michael Dean","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"},{"name":"Saskatoon Cancer Centre, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aalok","family":"Kumar","sequence":"additional","affiliation":[{"name":"BC Cancer Surrey, University of British Columbia, Surrey, BC V3V 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimira","family":"Alimohamed","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, AB T2N 4N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-318X","authenticated-orcid":false,"given":"Christine","family":"Brezden-Masley","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mds187","article-title":"Triple-Negative Breast Cancer: Epidemiological Considerations and Recommendations","volume":"23","author":"Boyle","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"djv048","DOI":"10.1093\/jnci\/djv048","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132011, Featuring Incidence of Breast Cancer Subtypes by Race\/Ethnicity, Poverty, and State","volume":"107","author":"Kohler","year":"2015","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10549-012-2315-y","article-title":"Clinical and Biologic Features of Triple-Negative Breast Cancers in a Large Cohort of Patients with Long-Term Follow-Up","volume":"136","author":"Malorni","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1245\/s10434-014-4279-0","article-title":"The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer","volume":"22","author":"Newman","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e4614","DOI":"10.1097\/MD.0000000000004614","article-title":"Features of Triple-Negative Breast Cancer","volume":"95","author":"Plasilova","year":"2016","journal-title":"Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1634\/theoncologist.2016-0067","article-title":"Biology and Management of Patients with Triple-Negative Breast Cancer","volume":"21","author":"Sharma","year":"2016","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13058-019-1210-4","article-title":"Current Treatment Landscape for Patients with Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer: A Systematic Literature Review","volume":"21","author":"Li","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013Drug Conjugates for Cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Huang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, Pathological, and PAM50 Gene Expression Features of HER2-Low Breast Cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low Breast Cancer: Pathological and Clinical Landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 Is a Novel Target for Solid Cancer Therapy with Sacituzumab Govitecan (IMMU-132), an Antibody-Drug Conjugate (ADC)*","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"ref_17","unstructured":"Gilead Sciences Canada, Inc. (2024, May 16). Product Monograph Including Patient Medication Information PrTRODELVY\u00ae. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00071772.PDF."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","article-title":"Sacituzumab Govitecan, a Novel, Third-Generation, Antibody-Drug Conjugate (ADC) for Cancer Therapy","volume":"20","author":"Goldenberg","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-Hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase I\/II IMMU-132-01 Basket Trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"A Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety Analyses from the Phase 3 ASCENT Trial of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.annonc.2022.03.187","article-title":"168P Sacituzumab Govitecan (SG) Efficacy in Patients with Metastatic Triple-Negative Breast Cancer (MTNBC) by HER2 Immunohistochemistry (IHC) Status: Findings from the Phase III ASCENT Study","volume":"33","author":"Hurvitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40262-024-01366-3","article-title":"Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors","volume":"63","author":"Sathe","year":"2024","journal-title":"Clin. Pharmacokinet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7","article-title":"Human TROP-2 Is a Tumor-Associated Calcium Signal Transducer","volume":"76","author":"Rapani","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ambrogi, F., Fornili, M., Boracchi, P., Trerotola, M., Relli, V., Simeone, P., La Sorda, R., Lattanzio, R., Querzoli, P., and Pedriali, M. (2014). Trop-2 Is a Determinant of Breast Cancer Survival. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096993"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 Quantitatively Stimulates Human Cancer Growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall Survival with Sacituzumab Govitecan in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"402","author":"Rugo","year":"2023","journal-title":"The Lancet"},{"key":"ref_32","first-page":"S663","article-title":"275TiP ASCENT-03: Phase III Study of Sacituzumab Govitecan (SG) vs. Treatment of Physician\u2019s Choice (TPC) in First-Line (1L) Metastatic Triple-Negative Breast Cancer (MTNBC)","volume":"33","author":"Bardia","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab Govitecan in Hormone Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_34","unstructured":"(2024, February 24). Sacituzumab Govitecan BC Cancer Drug Manual. Available online: http:\/\/www.bccancer.bc.ca\/drug-database-site\/Drug%20Index\/Sacituzumab%20govitecan_monograph.pdf."},{"key":"ref_35","unstructured":"BC Cancer (2024, May 15). BC Cancer Protocol Summary for Palliative Therapy for Metastatic Triple Negative Breast Cancer using Sacituzumab GovitecanProtocol Code: BRAVSG. Available online: http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Breast\/BRAVSG_Protocol.pdf."},{"key":"ref_36","unstructured":"(2024, February 20). Cancer Care Ontario Drug Formulary. Available online: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/70431."},{"key":"ref_37","unstructured":"(2024, February 20). Cancer Care Ontario Drug Formulary. Available online: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/drugs\/sacituzumabgovitecan."},{"key":"ref_38","unstructured":"NIH: ClinicalTrials.gov (2024, May 15). Preventive Strategy for IMMU132-Related AEs in TNBC\u2014PRIMED (PRIMED), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05520723?cond=Triple%20Negative%20Breast%20Cancer&term=PRIMED&intr=Sacituzumab%20Govitecan&rank=1."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Garcia, J.M.P., Gion, M., Ruiz-Borrego, M., Blancas, I., Lopez-Miranda, E., Blanch, S., Sabela, R., Calvo, L., Gonzalez, X., and Ancizar, N. (2024). Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+\/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. J. Clin. Oncol., 42.","DOI":"10.1200\/JCO.2024.42.16_suppl.1101"},{"key":"ref_40","unstructured":"(2024, May 29). NCCN Guidelines for Patients. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf."},{"key":"ref_41","unstructured":"Springer Link (2024, May 15). Table 3 Emetogenic Potential of Single Intravenous Antineoplastic Agents. Available online: https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08220-5\/tables\/3."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","article-title":"2023 Updated MASCC\/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following Moderately Emetic Risk Antineoplastic Agents","volume":"32","author":"Schwartzberg","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_43","unstructured":"BC Cancer (2024, May 15). BC Cancer Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults. Available online: http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Supportive%20Care\/SCNAUSEA_Protocol.pdf."},{"key":"ref_44","unstructured":"(2024, February 20). Cancer Care Ontario Guidelines and Advice. Antiemetic Recommendations for Chemotherapy-Induced Nausea and Vomiting: A Clinical Practice Guideline. Available online: https:\/\/www.cancercareontario.ca\/sites\/ccocancercare\/files\/guidelines\/full\/2019AntiemeticRecommendationsChemotherapyInducedNauseaVomiting.pdf."},{"key":"ref_45","unstructured":"Gilead Medical Information (2024, May 15). Trodelvy\u00ae (Sacituzumab Govitecan-Hziy) Hypersensitivity and Infusion-Related Reactions. Available online: https:\/\/www.askgileadmedical.com\/docs\/trodelvy\/trodelvy-hypersensitivity-and-infusion-related-reactions."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"CADTH (2022). CADTH Reimbursement Review Sacituzumab Govitecan (Trodelvy). Can. J. Health Technol., 2.","DOI":"10.51731\/cjht.2022.260"},{"key":"ref_47","unstructured":"(2024, May 01). BC Cancer. Available online: http:\/\/www.bccancer.bc.ca\/health-info\/coping-with-cancer\/managing-symptoms-side-effects\/hair-loss-appearance-changes#:~:text=Chemotherapy%20can%20cause%20hair%20loss,support%20a%20-healthy%20body%20image."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2017.07.012","article-title":"Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"18","author":"Rugo","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FPC.0000000000000024","article-title":"PharmGKB Summary: Very Important Pharmacogene Information for UGT1A1","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet Genom."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2478\/jomb-2018-0015","article-title":"Significance of UGT1A1*28 Genotype in Patients with Advanced Liver Injury Caused by Chronic Hepatitis C","volume":"38","author":"Jordovic","year":"2019","journal-title":"J. Med. Biochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10147-013-0562-5","article-title":"Association between Severe Toxicity of Nilotinib and UGT1A1 Polymorphisms in Japanese Patients with Chronic Myelogenous Leukemia","volume":"19","author":"Shibata","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jnci\/djm115","article-title":"UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters","volume":"99","author":"Hoskins","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1158\/1078-0432.CCR-10-1122","article-title":"Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk","volume":"16","author":"Hu","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic Variants in the UDP-Glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan","volume":"22","author":"Innocenti","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_55","unstructured":"GILEAD (2024). Highlights of Prescribing Information, GILEAD."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Nguyen, T.D., Bordeau, B.M., and Balthasar, J.P. (2023). Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers, 15.","DOI":"10.3390\/cancers15030713"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the Safety of Antibody\u2013Drug Conjugates for Patients with Solid Tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical Toxicity of Antibody Drug Conjugates: A Meta-Analysis of Payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA Oncology Analysis of Antibody-Drug Conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_60","unstructured":"NIH (2024, February 20). Sacituzumab Govitecan in Primary HER2-Negative Breast Cancer (SASCIA) (NCT04595565), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT04595565."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Tolaney, S.M., Demichele, A., Takano, T., Rugo, H.S., Perou, C., Metzger, O., Parsons, H.A., Santa-Maria, C.A., Rocque, G.B., and Yao, W. (2023). ASCENT-05\/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro \u00b1 capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery. J. Clin. Oncol., 41.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS619"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.2022.40.16_suppl.512","article-title":"Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients with Localized Triple-Negative Breast Cancer: Results from the NeoSTAR Trial","volume":"40","author":"Spring","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_63","unstructured":"FDA (2021). FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer, FDA."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S664","DOI":"10.1016\/j.annonc.2022.07.1860","article-title":"276TiP ASCENT-04\/KEYNOTE-D19: Phase III Study of Sacituzumab Govitecan (SG) plus Pembrolizumab (Pembro) vs. Treatment of Physician\u2019s Choice (TPC) plus Pembro in First-Line (1L) Programmed Death-Ligand 1-Positive (PD-L1+) Metastatic Triple-Negative Breast Cancer (MTNBC)","volume":"33","author":"Tolaney","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/422\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:01:51Z","timestamp":1760112111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":64,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["curroncol31090422"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31090422","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]}}}